PFE has an oral *non*-GLP-1 anti-obesity drug in phase-1, according to today’s JPM webcast. For competitive reasons, PFE is not disclosing the MoA. (I am not referring to PF-06954522, which is an oral GLP-1 in phase-1.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”